Brick & Kyle Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.24M | Sell |
19,482
-806
| -4% | -$179K | 1.4% | 24 |
|
|
2025
Q4 | $4.64M | Sell |
20,288
-115
| -0.6% | -$26.2K | 1.64% | 27 |
|
|
2025
Q3 | $4.72M | Buy |
20,403
+24
| +0.1% | +$4.89K | 1.74% | 24 |
|
|
2025
Q2 | $3.87M | Buy |
20,379
+21
| +0.1% | +$3.9K | 1.72% | 25 |
|
|
2025
Q1 | $4.26M | Sell |
20,358
-14,985
| -42% | -$2.91M | 1.95% | 22 |
|
|
2024
Q4 | $6.28M | Sell |
35,343
-211
| -0.6% | -$38.8K | 2.67% | 11 |
|
|
2024
Q3 | $7.01M | Sell |
35,554
-808
| -2% | -$151K | 3.01% | 10 |
|
|
2024
Q2 | $6.24M | Sell |
36,362
-626
| -2% | -$104K | 2.58% | 12 |
|
|
2024
Q1 | $6.56M | Sell |
36,988
-479
| -1% | -$82.6K | 2.91% | 11 |
|
|
2023
Q4 | $5.81M | Sell |
37,467
-221
| -0.6% | -$32.2K | 2.89% | 11 |
|
|
2023
Q3 | $5.62M | Buy |
37,688
+135
| +0.4% | +$19.8K | 2.98% | 9 |
|
|
2023
Q2 | $5.17M | Sell |
37,553
-116
| -0.3% | -$17K | 2.77% | 9 |
|
|
2023
Q1 | $6M | Sell |
37,669
-487
| -1% | -$74.5K | 3.44% | 7 |
|
|
2022
Q4 | $6.17M | Sell |
38,156
-678
| -2% | -$104K | 3.59% | 6 |
|
|
2022
Q3 | $5.28M | Buy |
38,834
+353
| +0.9% | +$50.7K | 3.2% | 7 |
|
|
2022
Q2 | $5.87M | Sell |
38,481
-16,907
| -31% | -$2.58M | 3.29% | 7 |
|
|
2022
Q1 | $8.98M | Sell |
55,388
-57,532
| -51% | -$8.36M | 4.36% | 6 |
|
|
2021
Q4 | $15.3M | Buy |
112,920
+58,231
| +106% | +$6.88M | 3.56% | 7 |
|
|
2021
Q3 | $5.63M | Buy |
54,689
+3,166
| +6% | +$362K | 2.86% | 10 |
|
|
2021
Q2 | $5.8M | Sell |
51,523
-271
| -0.5% | -$30.5K | 3.03% | 8 |
|
|
2021
Q1 | $5.64M | Sell |
51,794
-56
| -0.1% | -$5.99K | 3.12% | 7 |
|
|
2020
Q4 | $5.55M | Buy |
51,850
+603
| +1% | +$57.9K | 3.46% | 6 |
|
|
2020
Q3 | $4.44M | Buy |
51,247
+723
| +1% | +$68.1K | 3.07% | 8 |
|
|
2020
Q2 | $4.92M | Buy |
50,524
+1,082
| +2% | +$95.3K | 3.67% | 4 |
|
|
2020
Q1 | $3.77M | Buy |
49,442
+3,298
| +7% | +$281K | 3.54% | 8 |
|
|
2019
Q4 | $4.07M | Buy |
46,144
+410
| +0.9% | +$34K | 3.1% | 12 |
|
|
2019
Q3 | $3.58M | Buy |
45,734
+3,149
| +7% | +$216K | 2.97% | 12 |
|
|
2019
Q2 | $3.04M | Sell |
42,585
-1,146
| -3% | -$90.1K | 2.87% | 14 |
|
|
2019
Q1 | $3.52M | Sell |
43,731
-991
| -2% | -$81.1K | 3.61% | 10 |
|
|
2018
Q4 | $4.12M | Buy |
+44,722
| New | +$3.93M | 3.94% | 3 |
|
|
2018
Q2 | $4.29M | Sell |
46,300
-2,567
| -5% | -$251K | 3.36% | 3 |
|
|
2018
Q1 | $4.63M | Sell |
48,867
-1,076
| -2% | -$118K | 3.73% | 4 |
|
|
2017
Q4 | $4.83M | Sell |
49,943
-1,332
| -3% | -$126K | 3.93% | 3 |
|
|
2017
Q3 | $4.56M | Buy |
51,275
+171
| +0.3% | +$13K | 3.68% | 2 |
|
|
2017
Q2 | $3.71M | Sell |
51,104
-260
| -0.5% | -$17.5K | 3.18% | 3 |
|
|
2017
Q1 | $3.35M | Sell |
51,364
-312
| -0.6% | -$19.6K | 2.6% | 4 |
|
|
2016
Q4 | $3.24M | Buy |
51,676
+326
| +0.6% | +$19.9K | 2.6% | 6 |
|
|
2016
Q3 | $3.24M | Sell |
51,350
-154
| -0.3% | -$9.97K | 2.6% | 3 |
|
|
2016
Q2 | $3.19M | Sell |
51,504
-450
| -0.9% | -$27.4K | 2.61% | 4 |
|
|
2016
Q1 | $2.97M | Sell |
51,954
-591
| -1% | -$32.9K | 2.57% | 6 |
|
|
2015
Q4 | $3.11M | Sell |
52,545
-1,480
| -3% | -$85.2K | 2.74% | 4 |
|
|
2015
Q3 | $2.94M | Buy |
54,025
+835
| +2% | +$54.4K | 2.76% | 5 |
|
|
2015
Q2 | $3.57M | Sell |
53,190
-750
| -1% | -$49K | 3% | 2 |
|
|
2015
Q1 | $3.16M | Buy |
53,940
+1,790
| +3% | +$108K | 2.7% | 3 |
|
|
2014
Q4 | $3.41M | Buy |
+52,150
| New | +$3.29M | 2.95% | 2 |
|
Other funds holding ABBV
VCM
VPM
Brick & Kyle Associates's ABBV Position: Q1 2026 in Review
Brick & Kyle Associates reduced its AbbVie (ABBV) stake by 4% in Q1 2026, selling an estimated $179K and leaving 19,482 shares worth $4.24M. The position accounts for 1.4% of the portfolio, ranked #24.
Brick & Kyle Associates first reported a position in ABBV in Q4 2014 and has held it in 45 quarters since. The position peaked at $15.3M in Q4 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Brick & Kyle Associates held 19,482 shares of AbbVie worth $4.24M as of Q1 2026.
- Brick & Kyle Associates sold 806 AbbVie shares in Q1 2026, an estimated $179K.
- AbbVie made up 1.4% of Brick & Kyle Associates's portfolio in Q1 2026, its #24 holding.
- Brick & Kyle Associates first reported a position in AbbVie in Q4 2014 and has held it in 45 quarters since.
- Brick & Kyle Associates's AbbVie position peaked at $15.3M in Q4 2021.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Brick & Kyle Associates's 13F filing for Q1 2026, filed 2 Jul 2026.